DIK Stock Overview
Denka Company Limited manufactures and sells organic and inorganic materials to electronic materials and pharmaceuticals in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Denka Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥13.40 |
| 52 Week High | JP¥18.10 |
| 52 Week Low | JP¥13.40 |
| Beta | 0.50 |
| 1 Month Change | -8.84% |
| 3 Month Change | -13.55% |
| 1 Year Change | -25.97% |
| 3 Year Change | -60.12% |
| 5 Year Change | -49.40% |
| Change since IPO | -28.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| DIK | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | -5.0% | -1.5% | -1.5% |
| 1Y | -26.0% | -1.1% | 0.9% |
Return vs Industry: DIK underperformed the German Chemicals industry which returned -1.3% over the past year.
Return vs Market: DIK underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| DIK volatility | |
|---|---|
| DIK Average Weekly Movement | 3.8% |
| Chemicals Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DIK has not had significant price volatility in the past 3 months.
Volatility Over Time: DIK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1915 | 6,406 | Toshio Imai | www.denka.co.jp |
Denka Company Limited manufactures and sells organic and inorganic materials to electronic materials and pharmaceuticals in Japan and internationally. The company’s Electronics & Innovative Products division provides conductive agents for lithium for lithium-ion batteries, thermal materials and substrates, functional ceramics, films, and tapes. Its Life Innovation division works to improve people's life in the fields of prevention, diagnosis, and treatment, including influenza vaccines; test reagents, such as rapid testing kits for COVID-19; and macromolecular hyaluronate preparations.
Denka Company Limited Fundamentals Summary
| DIK fundamental statistics | |
|---|---|
| Market cap | €1.17b |
| Earnings (TTM) | €45.62m |
| Revenue (TTM) | €2.38b |
25.6x
P/E Ratio0.5x
P/S RatioIs DIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIK income statement (TTM) | |
|---|---|
| Revenue | JP¥391.67b |
| Cost of Revenue | JP¥305.37b |
| Gross Profit | JP¥86.30b |
| Other Expenses | JP¥78.79b |
| Earnings | JP¥7.51b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | 87.12 |
| Gross Margin | 22.03% |
| Net Profit Margin | 1.92% |
| Debt/Equity Ratio | 64.9% |
How did DIK perform over the long term?
See historical performance and comparison